

Date: 07/03/2018

FREEDOM OF INFORMATION REQUEST FOI 013948 - Asthma

1. In your trust, in the past 3 months [latest 3 months available], how many asthma patients aged 18 and over have been treated?

Identified by primary diagnosis on admission only, ED coding for asthma includes all conditions so not explicit. - 65

2. How many paediatric asthma treated patients [aged 6-17] have been treated? - 17

3. How many severe asthmatic patients [BTS guidelines, step 4 or 5] have been treated? - Around 200

4. How many severe allergic asthma patients [severe persistent confirmed allergic IgE-mediated asthma OR severe persistent confirmed allergic eosinophilic asthma] have been treated with:

- Omalizumab [Xolair] - 30
- Mepolizumab [Nucala] - Mepo they go to Heartlands
- Reslizumab [Cinqaero] - Nil
- Benralizumab [Fasenra] - Nil
- Other [Please state] - Nil

5. How many paediatric severe asthma patients treated with Xolair/omalizumab? - None

6. How many asthma clinics are run per month? - Two adult difficult asthma clinics per month and four omalizumab clinics

7. What is the average number of severe asthma patients per clinic? - 11 per clinic

8. Do you treat non asthma patients with Omalizumab [Xolair]? - no do not treat other things with omalizumab  
If yes, how many of for what condition? - N/AFOI/013948